Artery Therapeutics is a pre-clinical stage biotechnology company based in San Ramon, California. They utilize their technical and metabolic expertise to develop novel peptide-based therapies derived from apolipoprotein E. These peptides manipulate the ABCA1 transporter to alter cell membrane functionality and lipid composition. Their clinical candidate programs for neurodegenerative diseases and diabetes-generated cardiovascular disease are investigational new drug ready. Artery Therapeutics aims to provide effective treatments for neurodegenerative and metabolic diseases such as Alzheimer's disease, Lewy body dementia, and traumatic brain injury.